Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.42 - $18.16
Previous CloseN/A
Volume16.79K
Average Volume (3M)46.50K
Market Cap
$251.32M
Enterprise Value$185.82M
Total Cash (Recent Filing)$62.35M
Total Debt (Recent Filing)$1.75M
Price to Earnings (P/E)―
Beta-2.46
Next Earnings
Jun 13, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding50,977,560
10 Day Avg. Volume28,746
30 Day Avg. Volume46,499
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$21.57Price Target Upside362.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment in the pivotal cohort for high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients is on track to file BLA mid-2026.
Financial PositionENGN ended 1Q25 with $272.8mm in cash and equivalents, which is expected to fund operations.
Market PotentialENGN believes the BCG-unresponsive NMIBC market will grow significantly, potentially increasing from $2 billion to $20 billion, with detalimogene being a first-option in community urology offices.
Bears Say
Competitive LandscapeFeedback from key opinion leaders indicates urologists are prepared to sequence products, with detalimogene expected to be the first choice due to its efficacy, safety, and ease of administration.
Research And Development CostsResearch and Development costs of $20.0mm were above the consensus of $12.4mm, indicating higher than expected spending.
Stock ValuationInvestor sentiment has been influenced by cross-trial comparisons to more advanced programs—likely contributing to enGene’s stock trading near the lower end of its 52-week range.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $4.42 and its highest was $18.16 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $251.32M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Jun 13, 2025 which is in 77 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Mar 10, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.368 by -$0.112.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.5.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 50,977,560 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.368. Following the earnings report the stock price went down -1.718%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
---
enGene Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.57 (362.88% Upside)
$21.57 (362.88% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 550.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.97%
12-Months-Change
Fundamentals
Return on Equity
-44.21%
Trailing 12-Months
Asset Growth
206.07%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
---
ENGN Stock 12 Month Forecast
Average Price Target
$21.57
▲(362.88% Upside)
Technical Analysis
Biogen
―
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-39.00%
reiterated a buy rating 17 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.00% per trade.
---